Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial

BACKGROUND: Trauma is a leading cause of mortality and morbidity, with traumatic brain injury (TBI) and uncontrolled hemorrhage responsible for the majority of these deaths. Recombinant activated factor VIIa (rFVIIa) is being investigated as an adjunctive hemostatic treatment for bleeding refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Kluger, Yoram, Riou, Bruno, Rossaint, Rolf, Rizoli, Sandro B, Boffard, Kenneth David, Choong, Philip Iau Tsau, Warren, Brian, Tillinger, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206502/
https://www.ncbi.nlm.nih.gov/pubmed/17686152
http://dx.doi.org/10.1186/cc6092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206502/
https://www.ncbi.nlm.nih.gov/pubmed/17686152
http://dx.doi.org/10.1186/cc6092

Ejemplares similares